Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)

• ClinicalTrials.gov Identifier: NCT04346368
• Recruitment Status: Unknown
• First Posted: April 15, 2020
• Last Update Posted: April 15, 2020
• Sponsor: Guangzhou Institute of Respiratory Disease
• Collaborators: Guangzhou Eighth People's Hospital; Tongji Hospital; Guangzhou Cellgenes Biotechnology Co.,Ltd
• Information provided by (Responsible Party): ShiYue Li, Guangzhou Institute of Respiratory Disease

Study Description

Brief Summary:

Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe cases, it was found that aberrant pathogenic T cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm.Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with COVID-19.

Condition or disease	Intervention/treatment	Phase
Coronavirus Disease 2019 (COVID-19)	Biological: BM-MSCs; Biological: Placebo	Phase 1; Phase 2

Detailed Description:

COVID-19 has become a urgent and serious public health event that threatens human life and health globally. No specific pharmacological treatments are available to date for COVID-19.Patients contracting the severe form of the disease constitute approximately 15% of the cases which is characterized by extensive acute inflammation. In these severe cases, there will be rapid respiratory system failure.

MSCs have been employed extensively in cell therapy, which includes a plethora of preclinical research investigations as well as a significant number of clinical trials. Safety and efficacy have been shown in many clinical trials. Previous studies have shown that MSCs could significantly reduce inflammatory cell infiltration in lung tissue, reduce inflammation in lung tissue, and significantly improve lung The structure and function of tissues protect lung tissue from damage.The mechanisms underlying the improvements after MSC infusion in COVID-19 patients also appeared to be the robust antiinflammatory activity of MSCs. Recent studies also showed that intravenous MSC infusion could reduce the overactivation of the immune system and support repair by modulating the lung microenvironment after SARS-CoV-2 infection. MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection.

The purpose of this study is to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients With COVID-19.The respiratory function, pulmonary inflammation, clinical symptoms, pulmonary imaging, side effects, immunological characteristics will be evaluated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial
• Estimated Study Start Date: April 2020
• Estimated Primary Completion Date: December 2020
• Estimated Study Completion Date: December 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs); Conventional treatment plus BM-MSCs	Biological: BM-MSCs; Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).
Placebo Comparator: Placebo; Conventional treatment plus placebo	Biological: Placebo; Placebo

Outcome Measures

Primary Outcome Measures :

1. Changes of oxygenation index (PaO2/FiO2) [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   Evaluation of pneumonia improvement
2. Side effects in the BM-MSCs treatment group [ Time Frame: Baseline through 6 months ]
   Proportion of participants with treatment-related adverse events

Secondary Outcome Measures :

1. Clinical outcome [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea.
2. Hospital stay [ Time Frame: Baseline through 6 months ]
   days of the patients in hospital
3. CT Scan [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   Evaluation of pneumonia improvement
4. Changes in viral load [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   (deep sputum / pharyngeal swab / nasal swab / anal swab / tear fluid / stomach fluid / feces / blood or alveolar lavage fluid)
5. Changes of CD4+, CD8+ cells count and concentration of cytokines [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   Immunological status
6. Rate of mortality within 28-days [ Time Frame: From baseline to day 28 ]
   Marker for efficacy
7. Changes of C-reactive protein [ Time Frame: At baseline, 6 hour, Day 1, Day 3,Week 1, Week 2, Week 4, Month 6. ]
   Markers of Infection

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to performing study procedures

2. Age ≥18 years, and ≤75 years;

   A confirmed case of Covid-19. The criteria are as follows:

   Clinically diagnosed or suspected cases with one of the following etiological evidence: 1) SARS-CoV-2 nucleic acid is positive in respiratory or blood samples detected by RT-PCR; 2) virus sequence detected in respiratory or blood samples shares high homology with the known sequence of SARS-CoV-2.

3. Clinical classification is severe case: Meet any of the following:

1) Increased respiratory rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; 2) Peripheral capillary oxygen saturation (SpO2) ≤93% at rest ; 3)Partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa).

Exclusion Criteria:

1. Other types of viral pneumonia, or bacterial pneumonia.
2. The clinical classification is mild, moderate or critical;
3. Patients with malignant blood or solid tumor.
4. Pregnant or lactating women;
5. There are other situations or diseases that the investigator think are not suitable to participate in this clinical study or may be increased risk of the subject.
6. Patients with serious social and mental disability, inability/restriction of legal capacity;
7. Refusal to sign informed consent;
8. Patients with severe liver disease (eg Child Pugh score ≥ C, AST> 5 times upper limit of normal );
9. Patients with severe renal insufficiency (estimated glomerular filtration rate ≤30mL / min / 1.73m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.

Contacts and Locations

Contacts

Contact: Shiyue Li, MD; 86-20-83062885; lishiyue@188.com

Contact: Ming Liu, MD; 86-20-83062885; mingliu128@hotmail.com

Locations

China, Guangdong

Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 510120

Contact: Shiyue Li, MD 86-20-83062885 lishiyue@188.com

Sponsors and Collaborators

Guangzhou Institute of Respiratory Disease

Guangzhou Eighth People's Hospital

Tongji Hospital

Guangzhou Cellgenes Biotechnology Co.,Ltd

More Information

• Responsible Party: ShiYue Li, Professor, Guangzhou Institute of Respiratory Disease
• ClinicalTrials.gov Identifier: NCT04346368
• Other Study ID Numbers: SC-2020-01
• First Posted: April 15, 2020
• Last Update Posted: April 15, 2020
• Last Verified: April 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

COVID-19; Coronavirus Infections; Respiratory Tract Infections; Infections; Pneumonia, Viral; Pneumonia; Virus Diseases; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases